BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 6, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2018

View Archived Issues

Administration of erlotinib via soaked intraocular lenses prevents posterior capsule opacification

Read More

Actuate begins phase I/II trial of GSK-3beta inhibitor 9-ING-41 in advanced cancers

Read More

CDK7 inhibitor THZ-1 induces breast cancer-specific cell death by suppressing LIN9 expression

Read More

Targeting NKILA in CTLs as a promising new breast cancer immunotherapy strategy

Read More

Irisin and bone: good but complicated

Read More

Premature birth complication prevented by targeting microglia

Read More

FAAH inhibitor PF-04457845 ameliorates stress- and fear-related behavior in humans

Read More

HP-3070 is efficacious and safe for the treatment of schizophrenia in adults

Read More

Selatogrel significantly inhibits platelet aggregation in phase II studies

Read More

Pyramid Biosciences licenses TRK modulator from AstraZeneca

Read More

TK-90 shows promise for prevention of mucositis in clinical study

Read More

Corbus initiates phase III DETERMINE study based on phase II data in dermatomyositis

Read More

Positive phase II data presented in third proof-of-concept study of VX-150

Read More

First patient enrolled in pivotal phase III AGENT study of arfolitixorin

Read More

Topline data presented from phase Ia study of LX-9211

Read More

Spiral Therapeutics initiates phase I trial of new hearing loss drug, LPT-99

Read More

Eli Lilly patents OGA inhibitors

Read More

Myelin needs just the right amount of neighborliness

Read More

Enanta Pharmaceuticals divulges MAP3K5 inhibitors

Read More

DuoHexaBody-CD37 induces potent CDC in ex vivo B-cell lymphoma and leukemia patient samples

Read More

Abide Therapeutics identifies MGL inhibitors

Read More

CD45-AM ADC as promising new approach for safer conditioning prior to bone marrow transplant

Read More

Oxford University Innovation discovers beta-lactamase inhibitors as antibacterials

Read More

Taisho Pharmaceutical describes bacterial LpxC inhibitors

Read More

Phase III study of satralizumab in neuromyelitis optica spectrum disorder meets primary endpoint

Read More

Repigmentation therapy with Scenesse and NB-UVB effective in vitiligo

Read More

DMC recommends stopping phase III study of lumateperone for futility

Read More

Lilly signs collaboration and license agreement for Aduro's cGAS-STING pathway inhibitor program

Read More

PeptiDream and Nihon Medi-Physics enter peptide-radioisotope conjugate alliance

Read More

European Commission approves Dengvaxia for prevention of dengue

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 5, 2025.
  • Male hair loss

    Cosmo data positive for first new hair-loss approach in decades

    BioWorld
    Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing